Esperion Therapeutics, Inc. (ESPR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Esperion Therapeutics, Inc. (ESPR) is down 15.1% since the beginning of the year. At $3 per share, ESPR is trading 24.8% below its 52-week high of $4. Investors who bought $1,000 worth of ESPR shares 5 years ago would now be looking at an investment worth $151.

Esperion Therapeutics, Inc. (ESPR) has returned -15.14% so far this year and 199.05% over the past 12 months. Over the last ten years, ESPR has returned -15.52% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jun 26, 2013, ESPR's average daily return is +0.10%, while the average monthly return is +2.08%. At this rate, an investment would double in approximately 2.8 years.

Historically, 53% of months were positive and 47% were negative. The best month was Dec 2023 with a return of +124.8%, while the worst month was Mar 2023 at -74.3%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 8 months.

On a daily basis, ESPR closed higher 50% of trading days. The best single day was Mar 20, 2017 with a return of +74.1%, while the worst single day was Mar 16, 2023 at -54.3%.

Esperion Therapeutics, Inc. has an annualized alpha of 7.55%, beta of 1.25, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since June 27, 2013.

• This stock participated in 145.27% of S&P 500 Index downside but only 39.84% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ESPR ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Esperion Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Esperion Therapeutics, Inc. was 99.37%, occurring on May 14, 2025. The portfolio has not yet recovered.

The current Esperion Therapeutics, Inc. drawdown is 97.28%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Esperion Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Esperion Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.